OVERVIEW

Rapid developments in methods for cardiovascular (CV) disease risk evaluation and recent advances in pharmacological and procedural strategies for management of cardiometabolic risk factors have significantly improved our ability to identify and treat at-risk patients. Join our internationally renowned faculty for updates on contemporary understanding of cardiovascular disease risk algorithms, polygenic risk scores, biomarkers and CV risk, preventive imaging, and female specific risk factors and learn how to incorporate strategies for personalization of risk assessment for each of your unique patients.  Develop skills in recognizing the early, multi-system signs of cardiometabolic disease beyond the heart, including metabolic liver and renal diseases and consider newer pharmacological strategies for organ protection. Targeting obesity is now imperative, particularly in at-risk patients early in the cardiometabolic continuum. Advance your skills in designing a comprehensive management strategy that includes lifestyle, as well as groundbreaking anti-obesity medications and surgical approaches to weight management. The landscape of lipid pharmacotherapy has never been more expansive and the most recent expert guidance on incorporation of these agents into clinical practice will be considered. Presentations of complex patient cases from the real-world will stimulate challenging discussions among participants and expert panelists. And just to keep you at the absolute peak of your scientific evidence game, join us for a session on the Top Trials of 2023-24 in preventive cardiology and cardiometabolic health that will impact your patient care!

LEARNING OBJECTIVES

At the completion of this conference, participants should be able to:

1. Incorporate comprehensive cardiovascular risk assessment into routine clinical practice and personalize evaluation based on the patient’s unique risk profile.
2. Formulate treatment strategies to target obesity early in the cardiometabolic risk continuum.
3. Select pharmacotherapy for management of dyslipidemia and reduction of cardiovascular risk based on current scientific evidence and expert guidance.
4. Intervene early for renal and hepatic protection in patients with cardiometabolic disease.

ACCREDIATATION

The Medical University of South Carolina is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical University of South Carolina designates this live activity for a maximum of 12.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.